Biotech · Private company · Cambridge, MA, US

Eikonizo Therapeutics, Inc.

Track this companyFree. Adds Eikonizo Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards1

Next-Generation CNS-Penetrant HDAC6 Inhibitors: Proof-of-Principle in Parkinson's DiseaseFiscal year 2025 · $499.8KNIH RePORTER 1R43NS141467-01A1 · fetched Nov 12, 2026